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Fig 2. Ileostomy with cutaneous intestinal metaplasia. Before treatment (punch biopsy site at
4 o’clock; left). After treatment (right).
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was not increased. Overall, these findings suggested
a metaplastic phenomenon.
Our patient returned to clinic for suture removal
(Fig 2, left) and at that time was treated with
electrocoagulation on a focal 1-cm region of the
erosion. On follow-up visit, the treated erosion had
evidence of reepithelialization and additional areas
of the erosion were treated, with a total of 4 sessions
of electrocoagulation scheduled 4 weeks apart
(Fig 2, right). Repeat punch biopsy performed at
the conclusion of therapy was consistent with
cicatrix, without evidence of intestinal metaplasia.
Peristomal intestinal metaplasia has been rarely
described.1-4 We report a second case of intestinal
metaplasia in a flat peristomal ulcer without over-
granulation, with an emphasis on management of
this condition. The pathogenesis is hypothesized to
be related to dissemination of intestinal mucosal cells
into the peristomal skin during surgery, or the
promotion of colonic mucosa migration and growth
by bile salts in intestinal contents.5
In 1 previous case report of peristomal intestinal
metaplasia, the authors induced effective reepitheli-
alization of the erosion after 11 electrocoagulation
treatments,2 based on the hypothesis that destruction
of intestinal tubular glands eliminates the secreted
factors that may promote the erosion. Given reports
of primary adenocarcinoma at sites of intestinal
metaplasia,4 when evaluating a patient with a
peristomal erosion recalcitrant to therapy, it is
recommended that a biopsy be performed to
establish the nature of the peristomal skin changes
and to guide proper treatment and management.
Kseniya Golubets, MD,a Oana M. Radu, MD,b
Jonhan Ho, MD,b and Lisa M. Grandinetti, MD,
FAADaDepartment of Dermatologya and Department of
Dermatopathology,b University of Pittsburgh
Medical Center, Pittsburgh, Pennsylvania
Funding sources: None.
Conflict of interest: None declared.
Correspondence to: Lisa M. Grandinetti, MD,
FAAD, University of Pittsburgh, Department of
Dermatology, Presbyterian South Tower, Suite
3880, 200 Lothrop Street, Pittsburgh, PA 15213
E-mail: grandinettilm@upmc.edu
REFERENCES
1. Lyon CC, Smith AJ, Griffiths CE, Beck MH. The spectrum of skin
disorders in abdominal stoma patients. Br J Dermatol 2000;
143:1248-60.
2. Ono R, Oka M, Sakaguchi M, Kawakami F, Nagano T, Kunisada
M, et al. Peristomal skin ulcer with intestinal metaplasia. Br J
Dermatol 2012;167:204-6.
3. Johnson CD, White H. Colonic metaplasia with colonic-type
polyps on an ileostomy stoma in polyposis coli. Report of a
case. Dis Colon Rectum 1988;31:405-7.
4. Berman JJ, Ullah A. Colonic metaplasia of ileostomies.
Biological significance for ulcerative colitis patients following
total colectomy. Am J Surg Pathol 1989;13:955-60.
5. Strauch ED, Yamaguchi J, Bass BL, Wang JY. Bile salts regulate
intestinal epithelial cell migration by nuclear factor-kappa
B-induced expression of transforming growth factor-beta.
J Am Coll Surg 2003;197:974-84.
http://dx.doi.org/10.1016/j.jaad.2013.08.051
Angiosarcoma of the scalp successfully treated
with pazopanib
To the Editor: Angiosarcoma of the scalp has one of
the worst prognoses among malignant skin tumors.1
Standard treatment guidelines for angiosarcoma do
not currently exist.1 To the best of our knowledge,
this is the first case of angiosarcoma of the scalp
Fig 1. Angiosarcoma treated with pazopanib. Improvements in edema and erythema and a
reduction in the size of the left cheek indurated plaque are seen following pazopanib therapy.
A, Before pazopanib therapy. B, Fourteen days after the commencement of pazopanib therapy.
Fig 2. Angiosarcoma treated with pazopanib. Serial computed tomography scans. Scans show
varying responses in multiple intraparotid lymph nodes (arrows). A, Before pazopanib therapy.
B, Nineteen days after the commencement of pazopanib therapy.
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administration.
A 63-year-old man presented with scalp tumors
that had developed 2months earlier. Histopathologic
examination revealed atypical hyperchromatic
endothelial cells, which were positive for CD31,
CD34, D2-40, and VEGFR2 and which formed
vascular channels. The two tumors, 60 and 20 mm
in diameter, were excised with negative surgicalmargins; however, 4 additional surgical operations
were required to remove multiple recurrences.
Subsequently, weekly docetaxel (25 mg/m2, on
days 1, 8, and 15, and every 4 weeks thereafter)
was administered at 8 months after initial onset;
however, this treatment regimen failed to suppress
the development of further cutaneous tumors.
Therefore, intravenous recombinant interleukin-2
(7 3 105 U/day) combined with a 100-Gy electron
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months after onset. However, new tumors grew
outside the area of irradiation. At 18 months
after onset, the patient developed multiple ulcers
on the scalp, a 30- 3 20-mm indurated plaque on
the left cheek, marked edema of the face (Fig 1, A),
and enlargement of the involvement of multiple
cervical, mandibular, and intraparotid lymph nodes
(Fig 2, A).
Owing to the refractory nature of the tumors,
pazopanib treatment was initiated at a dose of
800 mg once daily. At day 3 of pazopanib
treatment, edema of the face began to subside,
and the patient began to open both eyes; the
edema finally disappeared by day 14. The left
cheek indurated plaque completely disappeared
(Fig 1, B). In addition, a computed tomography
scan at day 19 showed shrinking of the multiple
cervical, mandibular, and intraparotid lymph
nodes (Fig 2, B). Toxic side effects of grade 3
thrombocytopenia and grade 2 neutropenia were
apparent. Pazopanib therapy of 800 mg was
discontinued after 2 weeks and restarted at a
reduced dose of 600 mg once daily. Thereafter,
the appearance of grade 3 proteinuria required
that the dose be reduced further to 400 mg once
daily. However, partial tumor reduction has been
maintained for 26 weeks and the patient is now
undergoing a pazopanib treatment without toxic
side effects.
Pazopanib is a multi-targeted receptor tyrosine
kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3,
PDGFR-/, and c-kit.2 VEGFR-2 is up-regulated in
angiosarcoma.3 Angiosarcoma cells in the present
case were also positive for VEGFR-2, suggesting that
signals impinging on VEGFR-2 stimulate tumorigen-
esis. Accordingly, it is possible that pazopanib led to
clinical improvement by inhibiting VEGFR-2 tyrosine
kinase activity.
The administration of pazopanib results in rare
toxic effects.4 It is possible that taxane chemotherapy
contributed to these toxic effects.
Other VEGFR inhibitors (bevacizumab, sorafenib,
and sunitinib) have also been reported to be effective
treatments for angiosarcoma.1 Thus, VEGFR inhibi-
tors, such as pazopanib, may provide an additional
option for the treatment of angiosarcoma.
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Hypersensitivity to romidepsin
To the Editor: Romidepsin is a histone deacetylase
inhibitor that is FDA-approved for the treatment of
refractory cutaneous T-cell lymphoma (CTCL). It is
generally considered to be well tolerated, excluding
previously demonstrated hematologic toxicities.1 We
report a case of a hypersensitivity reaction to
romidepsin.
A 34-year-old black woman with stage IIIA CTCL
diagnosed in 2010 was started on romidepsin in April
2013 for refractory disease. Previous treatments
included psoralen with ultraviolet light A, extracor-
poreal photophoresis, interferon, bexarotene, and
doxorubicin with limited to no improvement. She
tolerated the first 2 cycles of romidepsinwell with the
initial dose administered at 10 mg/m2 and the
remaining doses at 14 mg/m2; however, she was
noted to have a low-grade fever, tachycardia,
burning sensation of her skin, and headache for 24
hours following each infusion. Immediately after
completion of the second 14-mg/m2 dose of cycle 3,
she became febrile to 39.58C, tachycardic to 150
bpm, hypotensive, and erythrodermic, necessitating
admission to the intensive care unit for emergent
resuscitation. Following stabilization and transfer to
